Ga-68 FAPI PET Before Immunotherapy
ConditionMesotheliomas Pleural
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAnkara University
About this trial
It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.
Eligibility criteria
Qualifiers
Having a histopathologically confirmed diagnosis of
Pleural Mesolthelioma
Patients scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy
Patients who gave informed consent form to participate in the study
Disqualifiers
ECOG>2
Patients who did not provide informed consent form to participate in the study
Trial design
Treatments tested in this trial
- Ga-68 FAPI PET/CT
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Ankara University
Lead sponsor
Liv Hospital Ankara
Collaborator
Social Sciences University of Ankara
Collaborator
Ankara Yildirim Beyazıt University
Collaborator
Source ClinicalTrials.gov